Do you find yourself frequently reaching for over-the-counter eye drops to help relieve your gritty, scratchy and irritated ...

Eye Drops for Red Eyes: LUMIFY significantly reduces redness to help reveal your eyes' natural radiance. From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and lasts up to 8 ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading ... and will not result in a transaction at this time." The eye care company said full separation remains the goal, according to the ...

There are also eye drops that can help with dry eyes caused by wearing contact ... we highly recommend the Sensitive Eyes Contact Lens Solution by Bausch + Lomb for anyone with sensitive eyes ...

Discover insights from Bausch + Lomb's Q4 2024 earnings call, highlighting 17% annual growth, innovative eye health solutions, and 2025 revenue projections.

Bausch + Lomb saw a broad-based growth across its three core segments. Vision care, its largest, saw revenue rise 9% to $723 million, while surgical increased 13% to $231 million. Pharmaceuticals rose ...

US FDA warns consumers over copycats of Bausch + Lomb eye drops January 31 ... a year after it completes its $1.75 billion deal for dry eye drug Xiidra, recently rehired chief executive Brent ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact lens ...

Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo, has shown ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch + Lomb private with a third-party buyer was one of several options being ...